Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

816729

registered interest
date	05/01/2018
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Human Papillomavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment his Department has made of the cost of extending the HPV vaccine to teenage boys.
tabling member constituency	Portsmouth South
tabling member printed	Stephen Morgan
uin	121156
answer	answer is ministerial correction date of answer 15/01/2018 answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI) is updating its advice on the potential extension of the human papillomavirus vaccination programme to include adolescent boys.</p><p> </p><p>An assessment of the overall costs of expanding the programme will be completed once JCVI’s final advice is received.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 15/01/2018 11:58:22 answering member 4067 label Biography information for Steve Brine
tabling member	4653 label Biography information for Stephen Morgan

802408

registered interest
date	06/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Human Papillomavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government, further to the Written Answer by Lord O'Shaughnessy on 5 December (HL3500), whether they will place a copy of the systematic review of serious adverse reactions following HPV vaccines, commissioned by the World Health Organisation, in the Library of the House.
tabling member printed	The Countess of Mar
uin	HL3941
answer	answer is ministerial correction date of answer 20/12/2017 answer text <p>The Global Advisory Committee on Vaccine Safety (GACVS) provides independent, authoritative, scientific advice to the World Health Organization (WHO) on vaccine safety issues. The GACVS public summary report dated 14 July 2017 states that it was presented with a draft of a systematic review of serious adverse events following human papillomavirus (HPV) vaccines that had been commissioned by WHO and summarises its findings. This found no difference in rates of selected serious adverse events between those exposed and unexposed to HPV vaccine. A copy of the systematic review, <em>Serious adverse events associated with HPV vaccination</em>, is attached.</p> answering member printed Lord O'Shaughnessy question first answered 20/12/2017 16:54:10 answering member 4545 label Biography information for Lord O'Shaughnessy attachment 1 file name HPV vaccination safety report _AHTA dec17.pdf title Serious adverse events associated with HPV
tabling member	1861 label Biography information for The Countess of Mar

793538

registered interest
date	22/11/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Human Papillomavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government whether they intend to place a copy of the systematic review of serious adverse reactions following HPV vaccines, commissioned by the World Health Organisation, in the Library of the House.
tabling member printed	The Countess of Mar
uin	HL3500
answer	answer is ministerial correction date of answer 05/12/2017 answer text <p>The World Health Organization’s Global Advisory Committee on Vaccine Safety publishes a summary outcome of its vaccine safety reviews on a six-monthly basis. The outcome of the Committee’s most recent review of human papillomavirus (HPV) vaccine safety was published on 14 July 2017. A copy of the <em>Weekly epidemiological record</em> is attached, which summarises the latest six month review. This review found no new adverse events of concern for HPV vaccine based on many very large, high quality studies.</p> answering member printed Lord O'Shaughnessy question first answered 05/12/2017 11:55:14 answering member 4545 label Biography information for Lord O'Shaughnessy attachment 1 file name GACVS 14 Jul 2017.pdf title Weekly epidemiological record
tabling member	1861 label Biography information for The Countess of Mar

788917

registered interest
date	14/11/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Human Papillomavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government, further to the Written Answer by Lord O'Shaughnessy on 2 November (HL2355) that no link has been established between HPV vaccines and chronic illness, what assessment they have made of the awards for damages made by the US Vaccine Court to 38 of 58 cases on this issue since 2016.
tabling member printed	The Countess of Mar
uin	HL3226
answer	answer is ministerial correction date of answer 27/11/2017 answer text <p>We have made no assessment of vaccine damage awards for human papillomavirus (HPV) vaccine in the United States as this is a matter for the US courts.</p><p>Thorough reviews undertaken by national and international scientific bodies have found no evidence to support a link between HPV vaccine and the development of chronic illnesses.</p> answering member printed Lord O'Shaughnessy question first answered 27/11/2017 13:09:58 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	1861 label Biography information for The Countess of Mar

786831

registered interest
date	10/11/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Human Papillomavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if his Department will publish (a) an assessment and (b) data supporting the responses to the Joint Committee on Vaccinations and Immunisation's consultation on extending HPV vaccination to boys; and how many and what proportion of submissions reported that vaccination.
tabling member constituency	Basildon and Billericay
tabling member printed	Mr John Baron
uin	112455
answer	answer is ministerial correction date of answer 15/11/2017 answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI) met on 4 October 2017 and discussed the responses from stakeholders to JCVI’s interim advice on whether to extend the human papilloma virus vaccination to boys. The minutes of 4 October JCVI meeting will be published on 15 November 2017 at:</p><p><a href="https://www.gov.uk/government/groups/joint-committee-on-vaccination-and-immunisation#publications-and-statements" target="_blank">https://www.gov.uk/government/groups/joint-committee-on-vaccination-and-immunisation#publications-and-statements</a></p> answering member constituency Winchester answering member printed Steve Brine question first answered 15/11/2017 11:48:09 answering member 4067 label Biography information for Steve Brine
tabling member	1390 label Biography information for Mr John Baron

785880

registered interest
date	07/11/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Human Papillomavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government, further to the Written Answer by Lord O'Shaughnessy on 2 November (HL2355), what are the latest figures for (1) suspected adverse events, and (2) serious adverse events, relating to (a) Gardasil, and (b) Cevarix, since those vaccines were introduced; and how many of those who reported serious adverse events remain incapacitated.
tabling member printed	The Countess of Mar
uin	HL3028
answer	answer is ministerial correction date of answer 20/11/2017 answer text <p>Through the Yellow Card Scheme, the Medicines and Healthcare products Regulatory Agency (MHRA) has received 9,007 reports of suspected adverse reactions (ADRs) to human papillomavirus (HPV) vaccine, up to the 6 November 2017. This follows administration of more than nine million doses of HPV vaccine in the United Kingdom. A breakdown by brand and severity is provided in the table below.</p><p> </p><table><tbody><tr><td><p> </p></td><td><p>Total</p></td><td><p>Serious</p></td></tr><tr><td><p>HPV brand unspecified</p></td><td><p>691</p></td><td><p>485</p></td></tr><tr><td><p>Cervarix</p></td><td><p>6,323</p></td><td><p>1,822</p></td></tr><tr><td><p>Gardasil</p></td><td><p>1,961</p></td><td><p>842</p></td></tr><tr><td><p>Gardasil 9</p></td><td><p>37</p></td><td><p>18</p></td></tr><tr><td><p>Total</p></td><td><p>9,007</p></td><td><p>3,162</p></td></tr></tbody></table><p><em>Source</em>: MHRA Sentinel database for ADRs.</p><p>It should be noted that the total number of reports received by vaccine brand is not equal to the totals in the table above, as some reports included more than one HPV vaccine brand.</p><p> </p><p>Each report may contain more than one symptom. Of the serious reports, 25% include a symptom that is recorded as not recovered. This is based on the information available on outcome at the time of reporting and cannot be used to determine the number of patients with persistent symptoms. While the MHRA encourages reporters to update the outcome, this is not always provided.</p><p> </p> answering member printed Lord O'Shaughnessy question first answered 20/11/2017 12:30:55 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	1861 label Biography information for The Countess of Mar

784910

registered interest
date	06/11/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Human Papillomavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, when he plans to publish the evaluation of the HPV vaccination pilot for men who have sex with men.
tabling member constituency	Brighton, Pavilion
tabling member printed	Caroline Lucas
uin	111700
answer	answer is ministerial correction date of answer 13/11/2017 answer text <p>The evaluation of the human papilloma virus vaccination pilot for men who have sex with men will be published in the near future.</p><p> </p><p>It will be published on the GOV.UK website at:</p><p> </p><p><a href="https://www.gov.uk/government/publications/hpv-vaccination-pilot-for-men-who-have-sex-with-men-msm" target="_blank">https://www.gov.uk/government/publications/hpv-vaccination-pilot-for-men-who-have-sex-with-men-msm</a></p><p><strong> </strong></p> answering member constituency Winchester answering member printed Steve Brine question first answered 13/11/2017 16:50:11 answering member 4067 label Biography information for Steve Brine
tabling member	3930 label Biography information for Caroline Lucas

784934

registered interest
date	06/11/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Human Papillomavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many men have received the HPV vaccine through the HPV vaccination pilot for men who have sex with men; and how many such men received (a) one dose, (b) two doses or (c) three doses of the vaccine.
tabling member constituency	Brighton, Pavilion
tabling member printed	Caroline Lucas
uin	111653
answer	answer is ministerial correction date of answer 17/11/2017 answer text <p>Data on the number of men who have received the human papilloma virus (HPV) vaccine through the HPV vaccination pilot for men who have sex with men and how many such men received each of the doses will be published in the near future.</p><p> </p><p>It will be published on the GOV.UK website at:</p><p><a href="https://www.gov.uk/government/publications/hpv-vaccination-pilot-for-men-who-have-sex-with-men-msm" target="_blank">https://www.gov.uk/government/publications/hpv-vaccination-pilot-for-men-who-have-sex-with-men-msm</a></p> answering member constituency Winchester answering member printed Steve Brine question first answered 17/11/2017 11:59:17 answering member 4067 label Biography information for Steve Brine
tabling member	3930 label Biography information for Caroline Lucas

782438

registered interest
date	02/11/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Human Papillomavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government, further to the Written Answer by Lord O'Shaughnessy on 1 November (HL2357), why all the symptoms reported for one individual are not correlated and recorded as occurring in that individual in the Medicines and Healthcare products Regulatory Agency records, instead of being recorded as discrete symptom reports.
tabling member printed	The Countess of Mar
uin	HL2861
answer	answer is ministerial correction date of answer 15/11/2017 answer text <p>When recording the details of an individual Yellow Card report, the Medicines and Healthcare products Regulatory Agency does assign all reported signs, symptoms and diagnoses to that individual case. Individual reports are evaluated in the context of all cumulative reports when reviewing safety.</p> answering member printed Lord O'Shaughnessy question first answered 15/11/2017 13:05:41 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	1861 label Biography information for The Countess of Mar

780496

registered interest
date	30/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Human Papillomavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many Yellow Cards submitted to the Medicines and Healthcare Products Regulatory Agency on the HPV vaccination have been classified as serious in the last three years.
tabling member constituency	Mansfield
tabling member printed	Ben Bradley
uin	110248
answer	answer is ministerial correction date of answer 07/11/2017 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) encourages anyone to report a suspected adverse reaction (ADR) to a vaccine or medicine through the Yellow Card Scheme:</p><p> </p><p><a href="http://www.mhra.gov.uk/yellowcard" target="_blank">www.mhra.gov.uk/yellowcard</a></p><p>A Yellow Card report is not proof of a side effect occurring, but a suspicion by the reporter that the vaccine or medicine may have been the cause. Such reports are kept under continual review to identify potential new risks.</p><p> </p><p>Between 31 October 2014 – 30 October 2017 a total of 649 serious suspected adverse reaction (ADR) reports with human papilloma virus (HPV) vaccines have been reported to the Medicines and Healthcare products Regulatory Agency (MHRA) via the Yellow Card Scheme (data run date: 1 November 2017). In this three year period, at least 1 million doses of HPV vaccine were administered in the United Kingdom.</p><p> </p><p>A breakdown of UK serious suspected spontaneous ADR reports received via the Yellow Card Scheme beween 31 October 2014 – 30 October 2016 by brand and year received is shown in the following table.</p><p> </p><table><tbody><tr><td><p>HPV Vaccine</p></td><td><p>Number of serious reports</p></td></tr><tr><td><p>HPV brand unspecified</p></td><td><p>181</p></td></tr><tr><td><p>Cervarix</p></td><td><p>64</p></td></tr><tr><td><p>Gardasil</p></td><td><p>390</p></td></tr><tr><td><p>Gardasil 9</p></td><td><p>18</p></td></tr><tr><td><p>Total</p></td><td><p>649</p></td></tr></tbody></table><p> </p><p>Source: MHRA sentinel database for adverse reactions</p><p> </p><p>Notes:</p><p> </p><p>The total number of reports received by vaccine brand is not equal to the totals in the table above as some reports included more than one HPV vaccine brand.</p><p> </p><p>The MHRA has received a total of 3,159 serious suspected adverse reaction reports associated with HPV vaccine (data run date 1 November 2017).</p><p> </p><p>All serious reports received via the Yellow Card Scheme are reviewed based on the details received from the reporter. Follow up letters may be sent for missing information such as vaccine brand name, batch number, medical history, results of investigations, diagnoses and details of outcome.</p><p> </p><p>The Commission on Human Medicines has thoroughly reviewed the safety of HPV vaccines and concluded that the evidence does not support a link between HPV vaccination and the development of chronic illnesses.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 110360 question first answered 07/11/2017 11:31:40 answering member 4067 label Biography information for Steve Brine
tabling member	4663 label Biography information for Ben Bradley